A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Patients with histologically or cytologically confirmed advanced malignant solid tumor, who have failed or cannot receive the standard treatment; * With at least one evaluable lesion according to RECIST v1.1 (for solid tumors); * Patients must be able to supply adequate tumor tissue for biomarker (including the expression of PD-L1, GARP) analyses; * Life expectancy longer than three months; * Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. Exclusion Criteria: * Has a concurrently active second malignancy, other than adequately treated non-melanoma skin cancers, in situ melanoma or in situ cervical cancer. Participants with history of the second malignancy have been disease-free for \<3 years. * Has a history of (non-infectious) interstitial lung disease (ILD) that required steroids, currently has ILD, or when suspected ILD cannot be ruled out by imaging at screening. * Participant has unresolved AEs ≥ Grade 2 from prior anticancer therapy except for alopecia. * Those who have received anti-GARP or anti-GARP/TGFβ complex antibody therapy.